Among various diseases, cancer is known as the “number one killer”. According to the 2012 China Tumor Registry Annual Report, there are about 3.12 million new cancer cases in China every year, with an average of 8,550 cases per day, 6 people are diagnosed with cancer every minute, and 5 people die from cancer. The incidence rate of liver cancer in China is the highest in the world. Liver cancer has become a disease that seriously endangers the health and life of our people. Statistics show that in 2008, there were 748,300 new cases of liver cancer and 695,900 deaths worldwide. China is a large country of liver cancer, and its incidence rate and mortality rate both account for more than half of the world. According to the 2012 China Tumor Registry Annual Report, the incidence rate of liver cancer in China ranks second after lung cancer, stomach cancer and colorectal cancer, while the mortality rate ranks second after lung cancer. In terms of the regional distribution characteristics of liver cancer, East, South and Northeast China are significantly higher than Northwest, Southwest and North China, and the coast is higher than the mainland, specifically, coastal areas such as Zhejiang, Guangxi and Jiangsu, as well as Inner Mongolia and Jilin are the high incidence areas of liver cancer in China. Liver cancer has become a disease that seriously endangers people’s health and life in China. Hepatitis B vaccination is an effective measure to prevent liver cancer The pathogenesis of liver cancer is not yet well understood. Scientific practice shows that hepatocellular carcinoma accounts for more than 90% of the incidence of primary liver cancer. Hepatocellular carcinoma is significantly different from other types of liver cancer in terms of pathogenesis, biological behavior, histological pattern, clinical manifestations, treatment methods and prognosis. When we talk about hepatocellular carcinoma in daily life, we mainly refer to hepatocellular carcinoma, whose development is related to hepatitis B, hepatitis C and cirrhosis caused by various reasons. More than 90% of liver cancer patients in China occur on the basis of hepatitis B or C. As many as 83.6% of liver cancer patients have cirrhosis in combination. Clinical statistics show that more than 80% of liver cancer patients are related to hepatitis B. China has implemented the hepatitis B vaccination strategy since 1992, and the hepatitis B virus carriage rate has decreased from 9.09% in 2002 to 7.18% in 2007, and now China has provided free hepatitis B vaccination to children under 15 years old. Universal hepatitis B vaccination is an effective measure to prevent hepatitis B and prevent the occurrence of liver cancer. Mother-to-child transmission of hepatitis B virus is an important way of hepatitis B transmission in China, and mother-to-child interruption is an important measure to prevent hepatitis B from occurring in newborns. When a mother with chronic hepatitis B gives birth to a child, she should give the infant high-valent immunoglobulin and hepatitis B vaccine in time to prevent the transmission of hepatitis B virus to her infant. By blocking hepatitis B, you also block most of the occurrence of liver cancer. All patients with hepatitis should be prohibited from consuming all types of beverages containing alcohol. All patients suffering from chronic migratory hepatitis (chronic hepatitis B and chronic hepatitis C) should actively take antiviral treatment under the guidance of doctors to inhibit the replication of virus in liver cells, control hepatitis virus always at low level, reduce liver cell damage, and thus reduce the occurrence of liver cancer. To avoid the occurrence of liver cancer, it is necessary to eliminate the consumption of various kinds of moldy foods, prevent drinking water pollution, quit smoking and limit alcohol, and maintain a healthy lifestyle. Ultrasonography and fetoprotein screening are important means to detect early liver cancer. Doctors often say “cancer should be detected and treated early”, but can liver cancer be detected early? Clinical statistics show that patients with liver cancer below 3 cm have a high surgical resection rate and survival rate, and the treatment effect is significantly better than that of patients with liver cancer above 3 cm. Patients with liver cancer usually have no clinical symptoms and signs in the early stage, and most patients still have no typical symptoms when the intrahepatic tumor reaches 3~5 cm, and few patients with early liver cancer are found to take the initiative to seek medical treatment. Universal liver cancer screening can detect liver cancer at an early stage. Ultrasonography and methemoglobin are important means to screen for early stage liver cancer. Ultrasound examination can detect tumors in the liver of 0.5 cm or above at an early stage; methemoglobin is an important marker of liver cancer, and its elevated index alerts patients to the possibility of liver cancer. Patients over 40 years old with chronic hepatitis B and C should undergo ultrasonography and methotrexate screening once every six months. For patients with cirrhosis, the screening interval should be shortened to every 3 months for ultrasonography and screening for methemoglobin. If liver nodules (often referred to as having occupying lesions in medicine) are found during screening, further CT, MRI-enhanced scan or digital subtraction angiography should be performed, and finally the nature of tumor should be clarified through pathological examination, so as to achieve early detection of liver cancer.” Minimally invasive treatment technology is an important means to treat liver cancer Early stage liver cancer surgical resection and liver transplantation are the traditional and most effective clinical treatment methods for liver cancer at present. However, because the liver has no sensory nerves, patients often go to the clinic only when they have self-conscious symptoms. Yes, most of the clinically diagnosed liver cancer patients are already in the middle and late stages of tumor development, and 80% of them lose the opportunity of traditional surgical resection and liver transplantation treatment. Fortunately, due to the continuous development of medical imaging equipment such as CT, MRI and ultrasound, the technology of minimally invasive treatment of tumors has been significantly advanced. At present, minimally invasive treatment techniques have become an important means of treating liver cancer. Clinicians use imaging equipment to guide minimally invasive surgical instruments, percutaneous puncture or perforation, which can directly reach the tumor lesion and perform minimally invasive surgeries such as radiofrequency ablation, microwave ablation, laser ablation and cryoablation on the tumor under real-time monitoring of imaging to remove the tumor in a targeted manner, changing the traditional open surgery mode. Minimally invasive surgery for cancer treatment applies tumor examination, treatment, monitoring and evaluation to the surgical process. Surgery is performed under image monitoring, and tumor treatment can be assessed immediately during surgery. Minimally invasive surgery for hepatocellular carcinoma is precisely localized, less traumatic, with fewer complications and a wide range of adaptations. It has a mild impact on the patient’s organism, can maximize the protection of human organ functions, and patients recover quickly after surgery. Clinical treatment results show that early stage liver cancer patients who are not suitable for traditional surgical resection or unwilling to undergo traditional surgical resection and more than 60% of middle and advanced stage liver cancer patients can receive minimally invasive ablative liver tumor removal surgery. At present, minimally invasive surgery for liver cancer in China has reached the international advanced level. For example, the Minimally Invasive Interventional Tumor Center of our hospital treated 487 patients with middle and late stage liver cancer with minimally invasive ablation surgery combined with arterial chemoembolization, and the largest tumor diameter of 12 cm was ablated. The treatment of hepatocellular carcinoma combined with portal vein cancer embolism has been an international medical challenge. The center uses arterial chemoembolization combined with radiofrequency or microwave ablation to treat 133 such patients in the past three years, with a 1-year survival rate of 87% and a 3-year survival rate of 41.4%. In addition to the above methods, doctors can also adopt radiotherapy and chemotherapy; apply molecular targeted drugs to control tumor growth as a whole; adopt radioimmunotherapy and gene therapy to remove tiny tumor lesions and reduce recurrence of liver cancer; and also adopt cell therapy, immunotherapy, Chinese medicine comprehensive treatment and other means. The progress of science and technology has made liver cancer a curable disease. Patients with liver cancer should build up confidence to overcome tumor and carry out active, scientific and systematic treatment under the guidance of medical personnel.